International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

computer with words expert commentary
Arnon Cohen Headshot

Arnon Cohen, MD, MPH, PhD
Clalit Health Services
Tel Aviv, Israel
IPC Councilor


Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Satveer K Mahil, Katie Bechman, Antony Raharja, et al. Lancet Rheumatol. 2022; Vol 4:e42–52.


In a study published in The Lancet Rheumatology, a research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity against SARS-CoV-2 spike glycoprotein in sixty-seven patients with psoriasis as compared to fifteen healthy controls after the second dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech). Patients included in the study received methotrexate (n=14), TNF inhibitors (n=19), IL-17 inhibitors (n=14), or IL-23 inhibitors (n=20). The median age was 44 years, with 52% males and 87% of White ethnicity. The study demonstrated that functional humoral immunity was not impaired by methotrexate or biologics, as observed that after the second dose of vaccine, as both patients and controls had neutralizing antibodies against wild-type SARS-CoV-2 and two variants. However, 38% of 13 participants on methotrexate and 26% of 50 participants on targeted biologics did not have detectable T-cell responses following the second dose of vaccine. There was no difference in the magnitude of T-cell responses between patients receiving methotrexate (median cytokine-secreting cells per 10⁶ cells 160, targeted biologics (169), and controls (185).

The observations on antibody development after COVID-19 vaccination in patients treated with methotrexate or targeted immunosuppressive agents are reassuring. However, the observation of absence of boosting of T-cell responses might indicate that durable cellular and humoral immunity may be impaired in some of the patients receiving these drugs.


  • Pending further investigations, the study by Mahil et al supports the prioritization of a further vaccine dose in patients with psoriasis receiving therapeutic immunosuppression, since 18 (29%) of their immunosuppressed cohort (63 patients) had undetectable cellular responses following a second dose.
  • It is essential to conduct studies with clinical outcomes in patients receiving immune-suppressive medications to assist clinical decision making about short-term treatment discontinuation at the time of vaccination or the need of additional booster vaccinations in these patients.
  • As the durability of antibody responses in the context of undetectable cellular responses is unknown, it is important that future research will focus on this aspect.


Limitations of the study are that patients with psoriasis not receiving immunosuppressants were not included, and that most participants were of White ethnicity. As the number of patients included and study and the duration of follow-up are limited, it is possible that differences may become statistically significant with a larger sample size or with longer follow-up.


Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)

Also Read


Psoriasis and the Pandemic: Lessons Learned from PsoProtect

The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.

Read More

Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.